Observes obinutuzumab with lenalidomide in people with returning follicular lymphoma
Observes obinutuzumab and lenalidomide treatment in adults with returning follicular lymphoma.
Key facts
- Who runs it
- Institute of Hematology & Blood Diseases Hospital, China
- Where
- Tianjin, ChinaSee the site
- Trial code
- Registry title
- Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study
- Status
- Recruiting
- People taking part
- 50 people, planned
- Started
- 1 Nov 2022
- Expected to end
- 31 May 2028
- Type of study
- Observational
- Record updated
- 23 May 2023
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose follicular lymphoma has come back or has not responded to earlier treatment, and who will be treated with obinutuzumab plus lenalidomide.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Follicular lymphoma that has come back or did not respond (relapsed or refractory) after front-line treatment. Earlier systemic treatment was for Stage III-IV disease.
- Earlier treatment
- At least one earlier line of systemic treatment for follicular lymphoma. Refractory means the tumor shrank by less than 50% or the disease progressed after 4 cycles of standard chemotherapy. It also includes relapse within 24 months after responding to standard chemotherapy, or 2 or more relapses.
Main reasons for not taking part
- Currently taking part in, or planning to join, any other interventional clinical trial
- Any other reason that, in the investigator's opinion, makes the study unsuitable for the patient
The registry criteria, word for word
Show all 8 criteriaShow less
Who cannot take part
- Patients currently participating or planning to participate in any interventional clinical trial
- Any other reason that, in the opinion of the investigator, makes the patient unsuitable for this study
Other criteria
- Patients must meet the following criteria for study entry::
- Signed Informed Consent Form
- Age ≥ 18 years at enrollment
- At least one prior line of systemic (Stage III-IV) follicular lymphoma therapy
- Relapsed or refractory to front-line anti-lymphoma therapy; refractory is defined as: tumor shrinkage of less than 50% or disease progression after 4 cycles of standard regimen chemotherapy; response to standard regimen chemotherapy, relapse within 24 months; 2 or more relapses, meeting one of the above criteria as refractory lymphoma
- Conditional treatment with obinutuzumab in combination with lenalidomide
Where in China
- Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical SciencesTianjin, ChinaContact: Rui LyuTaking people
About the trial
What the trial wants to find out
This study is planned to prospectively observe and verify the efficacy and safety of induction therapy with obinutuzumab in combination with lenalidomide followed by maintenance therapy with obinutuzumab and lenalidomide in patients with R/R FL in a real-world setting in a Chinese population.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Efficacy and Safety of Obinutuzumab in Combination With Lenalidomide in Patients With Relapsed and Refractory Follicular Lymphoma (R/R FL): A Prospective Observational Study
- Plain-language title
- Observes obinutuzumab with lenalidomide in people with returning follicular lymphomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 23 May 2023